KMT2A and acute myeloid leukemia: As shown by many previous studies, HOXA9 overexpression was observed in refractory MLL-rearranged ALL and AML patients (Gu et al., 2019; Haferlach et al., 2010; Kohlmann et al., 2008; Figure 1—figure supplement 1A–C).